文献速递银屑病与炎症性皮肤病

生物制剂治疗银屑病患者中难治部位的定位

Localization of treatment-resistant areas in patients with psoriasis on biologics.
PubMed 文献 · Br J Dermatol · 2019-05-07

这项观察性非干预研究纳入146例接受生物制剂治疗超过6个月的中重度银屑病患者,评估难治性皮损的解剖部位及其与生活质量的关系。结果显示最难治部位为前小腿(49.3%)、肘部(35.6%)、后小腿(24.7%)和头皮(19.2%),未观察到难治部位与皮肤病生活质量指数之间存在关联。

要点

  • 前小腿是生物制剂治疗银屑病患者中最常见的难治部位(49.3%)。
  • 肘部、后小腿和头皮也是常见的难治部位。
  • 难治性银屑病的具体部位与生活质量指数无关联。

核心结论

  • 在真实临床实践中,接受生物制剂治疗患者最常见的难治性银屑病部位为前小腿、后小腿和肘部。
  • 任何特定部位的难治性银屑病对生活质量的影响均不比其他部位更大。

研究设计与样本

  • 这是一项观察性、非干预性研究。
  • 研究对象为接受生物制剂治疗超过6个月的中重度银屑病患者,共纳入146例慢性斑块型银屑病患者(男性109例,占74.7%,平均年龄49.8±13.7岁)。
  • 部分或良好反应定义为银屑病面积和严重程度指数(PASI)评分≥1且≤5。
  • 由经验丰富的PASI评估者使用统一数据收集表,将体表分为26个区域和20个甲。

主要发现

  • 患者中位PASI评分为2.4(四分位距1.2-3.2),自治疗开始中位PASI下降86.1%(四分位距78.1-91.3)。
  • 最常见的难治部位为前小腿(49.3%;95%CI 41.2-57.4)。
  • 其他常见难治部位为后小腿(24.7%;95%CI 17.7-31.6)、肘部(35.6%;95%CI 27.8-43.4)和头皮(19.2%;95%CI 12.8-25.6)。
  • 未观察到皮肤病生活质量指数与特定难治性银屑病部位之间存在关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditionally, psoriasis in certain body sites such as the scalp, nails, palms, soles and intertriginous areas has been acknowledged as difficult to treat. OBJECTIVES: To investigate the body location of treatment-resistant psoriasis in patients treated with biologic agents in real-world clinical practice, and to study the association between localization and quality of life. METHODS: This was an observational, noninterventional, study. We investigated the skin and/or nail location of treatment-resistant psoriasis in patients with moderate-to-severe psoriasis treated for > 6 months with biologic agents. A partial or good response to treatment was defined as having a Psoriasis Area and Severity Index (PASI) score ≥ 1 and ≤ 5. Experienced PASI assessors used a uniform data collection form in which the body area was divided into 26 regions and 20 nails. RESULTS: We included 146 patients with chronic plaque-type psoriasis (109 men, 74·7%, mean ± SD age 49·8 ± 13·7 years), with a median PASI score of 2·4 (interquartile range 1·2-3·2). The median PASI reduction from treatment initiation was 86·1% (interquartile range 78·1-91·3). The most common site of recalcitrant psoriasis was the anterior lower leg [49·3%; 95% confidence interval (CI) 41·2-57·4]. Further common sites of recalcitrant psoriasis were the posterior lower leg (24·7%; 95% CI 17·7-31·6), elbow (35·6%; 95% CI 27·8-43·4) and the scalp (19·2%; 95% CI 12·8-25·6%). No association between Dermatology Life Quality Index and specific areas of recalcitrant psoriasis were observed. CONCLUSIONS: In real-world clinical practice, the most common sites of recalcitrant psoriasis in patients treated with biologic agents are the anterior lower leg, posterior lower leg and elbows. Recalcitrant psoriasis in no specific area caused a greater impact on quality of life than any other area.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019. PMID: 30677133. doi:10.1111/bjd.17689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。